4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherland and the United States. The company's lead product candidate, 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with a single, safe, and intravitreal injection; and 4D-710 for the treatment of cystic fibrosis through early-stage studies. It also develops 4D-175 for geographic atrophy in preclinical with open IND; 4D-725 for alpha-1 anti-trypsin deficiency lung disease in preclinical; and 4D-310 for Fabry disease, which is in Phase 1 clinical trials. The company has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; uniQure biopharma B.V; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics, Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM...

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Tempus AI, Inc. Class A (TEM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tempus AI, Inc. Class A (TEM) and 4D Molecular The...

Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and 4D Molecular Therapeutics (FDMT)

4D Molecular Therapeutics ( ($FDMT) ) has provided an update. On July 18, 2026, 4D Molecular Therapeutics reported positive two-year data from its ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FDMT	$13.83	+13.46%	1.72M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	FDMT	$13.83	+13.5%	1.72M
3
4
5
6

FDMT

Get 4D Molecular Therapeutics, Inc. Data in Excel

Get 4D Molecular Therapeutics, Inc. Data in Excel